Firebrick Pharma Limited · ASX:FRE
Firebrick Pharma — Shareholder Meeting (November 2025)
24 slides from Firebrick Pharma's shareholder meeting presentation, Nov 26, 2025
Slide 1: Annual General Meeting Presentation
For personal use only Presentation by Dr Peter Molloy Executive Chairman Annual General Meeting 26 November 2025 Authorised for release by Peter Molloy, Executive Chairman of Firebrick Pharma Limited The World Needs
Slide 2: Notice and Disclaimer
NOTICE AND DISCLAIMER This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation
Slide 3: Our primary asset: Nasodine Nasal Spray
Our primary asset: Nasodine® Nasal Spray • Firebrick successfully developed the world’s first clinically- For personal use only supported povidone-iodine nasal spray, Nasodine® Nasal Spray (“Nasodine”). • In vitro, Nasodine kills all known respiratory viruses and bacteria – including pandemic viruse
Slide 4: 2025 achievements and 2026 plans
For personal use only 2025 achievements 2026 plans “CY” refers to Calendar Year (Jan-Dec) “FY” refer to Financial Year (Jul-Jun) AGM Presentation 2025 Firebrick Pharma Ltd | 4
Slide 5: USA
USA Managed via Firebrick Pharma, Inc. (a wholly-owned US subsidiary) Nasodine marketed as a ‘nasal cleanser’ • CY25 achievements For personal use only • Increased online sales through our US e-commerce platform (nasodine.com). • Added distribution through online pharmacy (israelpharm.com/online-pha
Slide 6: Singapore
Singapore • CY25 achievements For personal use only • Retail distribution through Guardian pharmacies; Nasodine won ‘Best Newcomer’ award • Growth in online sales (nasodine-sg.com) • Nasodine now available in all government hospitals • License agreement with Innorini Life Sciences (“Innorini”): help
Slide 7: Fiji and South Pacific
Fiji and South Pacific • CY25 achievements For personal use only • Executed license agreement with local pharmaceutical partner, Makans Ltd • First order received from Makans • Promotion of Nasodine to HCPs and distribution started through retail pharmacies in Fiji • Promotion to tourists at Nadi ai
Slide 8: The Philippines
The Philippines • CY25 achievements For personal use only • Strategic investment in Firebrick by SV More Pharma Corporation (via Pharma Nutria N.A. Inc.) of $1.2 million • Successful manufacturing of two batches of Nasodine Nasal Spray in March 2025 • Regulatory approval application expected to be f
Slide 9: Beyond existing Nasodine markets
Beyond existing Nasodine markets • Australia For personal use only • We will continue discussions with TGA about potential pathways for approval of Nasodine in Australia • New Markets • We are actively pursuing new markets and partnerships for Nasodine in several countries in Southeast Asia where th
Slide 10: New Products: Nasodine Throat Spray
New Products: Nasodine Throat Spray • Nasodine Throat Spray is the first of several For personal use only new Nasodine products planned for introduction in CY26 • Features of Nasodine Throat Spray • Compact, convenient and less messy alternative to throat gargles • Targeted applicator to direct spra
Slide 11: Operating costs, funding and board
Operating costs, funding and board • Operating costs For personal use only • Despite growing our markets and developing new products, during CY25, we saw no significant growth in our operating cost base and expect it to remain at a similar level in CY26 • Funding • In CY25, we received $250,000 in R
Slide 12: Shareholder Sentiment & Nasodine User Feedback
For personal use only Shareholder Sentiment & Nasodine User Feedback Results of surveys conducted in October and November 2025
Slide 13: Shareholder Sentiment Survey
Shareholder Sentiment Survey • At 11 November 2025, Firebrick had nearly 3,800 registered For personal use only shareholder accounts representing an estimated 3,575 individual shareholders, based on common addresses • At that time, we had email contact details for around 1,270 of the individual shar
Slide 14: How does Firebrick perform as a public company?
Shareholder Sentiment Survey How does Firebrick perform as a public company? How does Firebrick perform as a public company? Above Average For personal use only + Outstanding Transparent, truthful 12% 43% 26% 17% 69% Commercially focused 16% 46% 23% 10% 69% Ethical, trustworthy 14% 43% 24% 15% 68% C
Slide 15: Goals for the next months
Shareholder Sentiment Survey Goals for the next 12 months What should Firebrick's priorities be for the next 12 months? For personal use only Get Nasodine approved in Australia 7% 24% 68% Significantly grow the US business 8% 31% 59% Sign licensing deals for new markets 5% 38% 56% Launch Nasodine in
Slide 16: Most important attributes of Nasodine to shareholders
Shareholder Sentiment Survey What are the most important attributes of Nasodine to shareholders? The most important attributes of Nasodine For personal use only It is clinically proven to be safe 11% 84% Kills all viruses that cause respiratory illness 12% 79% Kills SARS-CoV-2, the cause of COVID 14
Slide 17: Have you imported Nasodine from Singapore into Australia?
Shareholder Sentiment Survey Have you bought Nasodine Nasal Spray from Singapore and For personal use only imported it into Australia for personal use? 80% 70% 60% 50% 40% 72.3% 30% 20% 10% 27.7% 0% Yes No AGM Presentation 2025 Firebrick Pharma Ltd | 17
Slide 18: Shareholder comments – summary of key feedback
Shareholder Sentiment Survey Shareholder comments – summary of key feedback • Positive For personal use only • Many shareholders commented about the openness of the company and its willingness to engage with shareholders, including through regular email updates and HotCopper • Many also appreciated
Slide 19: Nasodine User Survey
Nasodine User Survey • In addition to the shareholder survey, we recently For personal use only conducted a Nasodine user survey to gain insights into verified users’ experiences with Nasodine • Around 850 Australians have now purchased Nasodine from Singapore for their personal use in the past 12 m
Slide 20: Why did you decide to use Nasodine?
Why did you decide to use Nasodine? For personal use only It kills all the germs that cause colds and flu 3% 35% 62% To protect myself and my family from any 6% 33% 61% respiratory infections It is clinically proven to be safe and effective 6% 36% 57% It is backed by peer-reviewed publications 12% 3
Slide 21: What did you use Nasodine for?
What did you use Nasodine for? Treatment of the common cold, whenever I get For personal use only 13% 20% 67% symptoms To protect myself from colds and flu (if exposed 11% 22% 67% to others with symptoms) Prevention or treatment of COVID 37% 22% 42% Treatment of sinusitis 57% 23% 21% As a nasal clea
Slide 22: Effectiveness and ease of use ratings
For your most frequent use, how would you rate Nasodine’s EFFECTIVENESS and EASE OF USE? How effective was Nasodine in your opinion? For personal use only 4% 26% 36% 33% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Not effective at all Slightly effective Effective Very effective Extremely effective H
Slide 23: Key findings from the user survey
Key findings from the user survey • In a post-COVID world, the fact that Nasodine kills all For personal use only respiratory viruses and can be used to protect people from respiratory illness, are very strong attractions to the product • The fact that it has been clinically proven to be safe and is
Slide 24: In closing…
In closing… • Firebrick has a clear sense of its purpose, direction and For personal use only priorities • Firebrick understands the needs of its shareholders and will strive to meet those needs and continue to communicate openly and honestly with all shareholders • Nasodine is not currently availab
Firebrick Pharma — Shareholder Meeting (November 2025) on 6ix